LAE 118
Alternative Names: LAE-118Latest Information Update: 19 Dec 2024
At a glance
- Originator Laekna Therapeutics
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer